


PHARMACEUTICAL 2020

Phathom Pharmaceuticals Inc. Rank 310 of 362







PHARMACEUTICAL 2020

Phathom Pharmaceuticals Inc. Rank 310 of 362

The relative strengths and weaknesses of Phathom Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Phathom Pharmaceuticals Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 185% points. The greatest weakness of Phathom Pharmaceuticals Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 419% points.

The company's Economic Capital Ratio, given in the ranking table, is -548%, being 245% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	255,601
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,748
Liabilities, Non-Current	2,698
Other Assets	1,114
Other Compr. Net Income	0
Other Expenses	78,897
Other Liabilities	22,777
Other Net Income	-148,916
Property and Equipment	463
Research and Development	20,374
Revenues	0
Selling, General and Administrative Expense	6,944

Output Variable	Value in 1000 USD
Assets	257,178
Liabilities	29,223
Expenses	106,215
Stockholders Equity	227,955
Net Income	-255,131
Comprehensive Net Income	-255,131
Economic Capital Ratio	-548%

